Effects of stopping aspirin in older adults with Alzheimer's and related dementias
Official title: Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias
Funded at Univ of North Carolina Chapel Hill · NIH-11015803 · Data updated 2026-11-12
This study is looking at what happens when older adults with Alzheimer's Disease and related dementias stop taking low-dose aspirin, which is usually taken to help prevent heart problems, to help figure out the best choice for their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | April 15, 2023 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $566,223 |
| NIH project number | 5R01AG079219-03 |
| Project ID | NIH-11015803 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults aged 65 and above who have been diagnosed with Alzheimer's Disease or related dementias and are currently taking low-dose aspirin.
✕Less likely to help
Patients who are younger than 65 or do not have Alzheimer's Disease or related dementias may not benefit from this research.
What this research studies
This research investigates the health outcomes of discontinuing low-dose aspirin in older adults who have Alzheimer's Disease and Related Dementias (ADRD). It aims to understand the risks and benefits of stopping aspirin, which is often used for heart disease prevention, in this specific population. The study will gather real-world data to help inform decisions about whether older adults with ADRD should continue or stop taking aspirin, considering their unique health needs. By examining the potential impacts on both cardiovascular health and cognitive function, the research seeks to provide clearer guidance for patients, caregivers, and healthcare providers.
Why it matters
Potential benefit: If successful, this research could lead to better-informed decisions regarding aspirin use in older adults with Alzheimer's and related dementias, potentially improving their overall health outcomes.
How similar studies have gone: While there is limited data on aspirin use specifically in older adults with ADRD, similar studies in other populations have shown varying outcomes, indicating that this research could provide novel insights.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Thorpe, Carolyn Timberlake — Univ of North Carolina Chapel Hill
- Study coordinator: Thorpe, Carolyn Timberlake
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.